These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 16912159

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
    Xing WJ, Zou Y, Han QL, Dong YC, Deng ZL, Lv XH, Jiang T, Ren H.
    Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
    Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL.
    PLoS Med; 2008 Jan 22; 5(1):e8. PubMed ID: 18215105
    [Abstract] [Full Text] [Related]

  • 5. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
    Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS.
    N Engl J Med; 2005 Nov 10; 353(19):2012-24. PubMed ID: 16282176
    [Abstract] [Full Text] [Related]

  • 6. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A.
    Mol Cancer Res; 2010 Aug 10; 8(8):1142-51. PubMed ID: 20647329
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy.
    Kim EJ, Jeong JH, Bae S, Kang S, Kim CH, Lim YB.
    J Cell Biochem; 2013 Jun 10; 114(6):1248-56. PubMed ID: 23592446
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.
    Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA.
    Cancer Res; 2007 Sep 01; 67(17):7960-5. PubMed ID: 17804702
    [Abstract] [Full Text] [Related]

  • 14. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN, Bucki R, Wlodarski P, Wasik MA.
    Oncogene; 2007 Aug 16; 26(38):5606-14. PubMed ID: 17353907
    [Abstract] [Full Text] [Related]

  • 15. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B, Chang CM, Yuan M, McKenna WG, Shu HK.
    Cancer Res; 2003 Nov 01; 63(21):7443-50. PubMed ID: 14612544
    [Abstract] [Full Text] [Related]

  • 16. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells.
    Azzariti A, Porcelli L, Gatti G, Nicolin A, Paradiso A.
    Biochem Pharmacol; 2008 Mar 01; 75(5):1035-44. PubMed ID: 18191814
    [Abstract] [Full Text] [Related]

  • 17. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
    Guillamo JS, de Boüard S, Valable S, Marteau L, Leuraud P, Marie Y, Poupon MF, Parienti JJ, Raymond E, Peschanski M.
    Clin Cancer Res; 2009 Jun 01; 15(11):3697-704. PubMed ID: 19435839
    [Abstract] [Full Text] [Related]

  • 18. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter.
    Pore N, Liu S, Haas-Kogan DA, O'Rourke DM, Maity A.
    Cancer Res; 2003 Jan 01; 63(1):236-41. PubMed ID: 12517803
    [Abstract] [Full Text] [Related]

  • 19. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions.
    Kaper F, Dornhoefer N, Giaccia AJ.
    Cancer Res; 2006 Feb 01; 66(3):1561-9. PubMed ID: 16452213
    [Abstract] [Full Text] [Related]

  • 20. Akt demoted in glioblastoma.
    Vogt PK, Hart JR.
    Sci Signal; 2009 Apr 21; 2(67):pe26. PubMed ID: 19383977
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.